Prosecution Insights
Last updated: October 27, 2026

Eric Jason Rogers, USPTO Patent Examiner

Listed by the USPTO as ROGERS, ERIC JASON

Tech Center 3900 • Art Units: 1612 1631 1638 1657 1699 3991

This examiner grants 57% of resolved cases

Analysis

ROGERS, ERIC JASON is assigned to tech center 3900 and art unit 1612. The record shows 109 resolved cases, a 56.9% allowance rate, and a median of 1427 days to allowance. The 33.2% interview lift identifies interviews as an important outcome-associated feature in this profile.

Porosome Therapeutics Inc., Iregene Therapeutics Ltd., and Editas Medicine Inc. are the listed companies. The listed firms are CANTOR COLBURN LLP, Casimir Jones, S.C., and MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP. The combination of the allowance figure and median timing suggests that applicants should plan for extended prosecution while evaluating whether an interview may improve the path to allowance.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

56.9%
Allow Rate
-3.1% vs TC avg
160
Total Applications
+33.2%
Interview Lift
1427
Avg Prosecution Days
Based on 109 resolved cases, 2023–2026

Rejection Statute Breakdown

5.0%
§101 Eligibility
15.0%
§102 Novelty
33.2%
§103 Obviousness
33.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18537754 SELECTION BY ESSENTIAL-GENE KNOCK-IN Final Rejection Editas Medicine, Inc.
17323715 GENERATION OF HOXA-EXPRESSING HEMOGENIC ENDOTHELIUM WITH ENHANCED T CELL POTENTIAL FROM HPSCS Non-Final OA Wisconsin Alumni Research Foundation
17609957 INDUCED HUMAN COLITIC ORGANOIDS Final Rejection The Cleveland Clinic Foundation
17599028 USE OF ONCOLYTIC VIRUSES IN THE NEOADJUVANT THERAPY OF CANCER Non-Final OA AMGEN INC.
17916683 METHODS TO ENRICH ENTEROENDOCRINE CELLS AND THEIR SUBTYPES IN THE CONTIGUOUS, INTESTINAL MONOLAYER SYSTEMS Non-Final OA University of Washington
18715012 HUMAN CORTICAL ORGANOIDS WITH ENGINEERED MICROGLIA-LIKE CELLS Non-Final OA Yale University
18018787 IN VITRO DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS Final Rejection VERTEX PHARMACEUTICALS INCORPORATED

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Eric Jason Rogers's allowance rate?

56.9% of resolved applications examined by Eric Jason Rogers were allowed (109 resolved cases), compared with 40.7% across Art Unit 1612 over the last five years.

Does an interview help with examiner Eric Jason Rogers?

This examiner's interview lift is +33.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Eric Jason Rogers take to allow a patent?

Applications allowed by Eric Jason Rogers took 1,427 days on average from filing to allowance.

Which art unit does examiner Eric Jason Rogers work in?

Eric Jason Rogers examines applications in Art Unit 1612 in Tech Center 3900.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month